Research Information System
Frontiers in Medicine, no.13, pp.1-11, 2026 (Scopus)
Background:
This study aimed to evaluate the potential of microRNA (miRNA)-210 as a biomarker for distinguishing iron deficiency anemia (IDA) from functional iron deficiency (FID) in hemodialysis (HD) patients. The diagnostic performance of miRNA-210 was also compared with conventional biochemical markers, including hemoglobin (Hb), ferritin, transferrin saturation (TSAT), and zinc protoporphyrin (ZnPP).
Methods:
Fifty HD patients were classified into control, IDA, and FID groups according to Hb, ferritin, and TSAT criteria. Pre-dialysis blood samples were collected, and plasma miRNA-210 levels were measured using reverse transcription quantitative polymerase chain reaction (RT2-PCR). Diagnostic performance was assessed through receiver operating characteristic (ROC) analysis alongside traditional biomarkers.
Results:
Plasma miRNA-210 levels were significantly higher in the IDA group compared to both the control (p = 0.0010) and FID (p = 0.0007) groups. A significant negative correlation was observed between miRNA-210 and Hb (ρ = −0.363, p = 0.0155). ROC analysis showed that miRNA-210 had moderate diagnostic discriminatory ability for differentiating IDA (AUC = 0.711, p = 0.0186). Its performance was comparable to ZnPP and exceeded to ferritin and TSAT.
Conclusion:
miRNA-210 may serve as a supportive biomarker, reflecting the interaction between hypoxia and iron metabolism in distinguishing IDA from FID among HD patients. These findings indicate that miRNA-210 could provide additional value in understanding anemia pathophysiology and enhance diagnostic evaluation.
Limitations:
Key limitations include the small sample size, single-center, cross-sectional design, absence of a healthy control group, and lack of molecular-level functional validation. Larger multicenter studies are needed to confirm these findings and determine clinically relevant cut-off values for miRNA-210.